Nelson Vergel Beyond Testosterone Podcast
By early 2026, the psychedelic medicine sector has entered a critical period of clinical and regulatory maturation marked by both significant breakthroughs and institutional challenges. While the FDA’s rejection of MDMA-assisted therapy necessitated stricter trial designs across the industry, Compass Pathways achieved a historic milestone with the first successful Phase 3 psilocybin results. Major pharmaceutical players have signaled confidence in the field, highlighted by AbbVie's billion-dollar acquisition of a novel tryptamine program. Multiple substances, including LSD, DMT, and ketamine derivatives, are currently advancing through late-stage testing for conditions like depression, anxiety, and PTSD. Consequently, a potential shift toward streamlined FDA approval policies may soon allow these once-stigmatized compounds to enter the mainstream medical market. Currently, the landscape is defined by a diverse pipeline of breakthrough-designated therapies nearing final regulatory decisions.
36 afleveringen
Reacties
0Wees de eerste die een reactie plaatst
Meld je nu aan en word lid van de Nelson Vergel Beyond Testosterone Podcast community!